Many biologics in development present stability issues during manufacture and in storage. Recombinant proteins, single chain antibodies, fusion proteins, nucleic acids and vaccines are often unstable, in many cases promising therapeutic candidates may not be taken forward into development due to stability issues.

Arecor has been able to demonstrate that the Arestat™ formulation technologies can address most physical and chemical degradation pathways, resulting in remarkably improved stability in a wide range of biologics (see Case Studies).